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Primary papillary epithelial tumour of the sella: expanding the spectrum of TTF-1-positive sellar
lesions
Aim: To describe four novel primary epithelial tumours
of the sella with papillary architecture and Thyroid Tran-
scription Factor 1 (TTF-1) expression. Methods: Paraffin-
embedded tissue from the four cases and recurrence of
patient 1 was investigated with haematoxylin–eosin,
special histochemical stains, immunohistochemistry
with a broad panel of antibodies and next-generation
sequencing. The ultrastructure of one tumour was stud-
ied in tissue retrieved from paraffin. Results: The lesions
occurred in three females aged 20, 26 and 42 years and
a male aged 49 years. They presented with signs and
symptoms secondary to pituitary stalk compression. Pre-
operative neuroimaging documented mixed solid and
cystic, enhancing sellar masses with suprasellar exten-
sion. Histologically, the tumours showed thin papillae
lined by a single layer of cytokeratin and TTF-1-positive
cuboidal and cylindrical cells with mildly atypical
nucleus. Next-generation sequencing performed in three
cases did not identify any mutations. The main differen-
tial diagnosis included metastasis from lung or thyroid
carcinoma, extraventricular choroid plexus papilloma
and sellar ependymoma. Conclusion: We suggest the
descriptive term of primary papillary epithelial tumour of
the sella (PPETS) for this entity and propose that it could
represent the intracranial equivalent of thyroid-like low-
grade nasopharyngeal papillary adenocarcinoma. The
cell of origin of PPETS remains undetermined although
the intense and ubiquitous expression of TTF-1 may sug-
gest a derivation from the infundibulum or ventricular
recess. Our study expands the spectrum of sellar TTF-1-
positive tumour and challenges the view that they all
derive from pituicytes.
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Introduction
Primary non-neuroendocrine tumours of the pituitary
gland account for about 10% of sellar region neo-
plasms. Of these, about 1% comprises lesions includ-
ing the group of Thyroid Transcription Factor-1
(TTF-1)-expressing tumours of the posterior lobe, neu-
ral and para-neuronal tumours, salivary gland-like
tumours, ectopic choroid plexus papilloma (eCPP),
primary sellar melanocytic neoplasms and primary
sellar atypical teratoid rhabdoid tumours [1-3]. Due
to their rarity, the last four entities have not been
included in the WHO Classification of Pituitary
Tumours [4].
Thyroid Transcription Factor-1 is a 38kDa nuclear
DNA-binding protein that belongs to the NKX2 home-
odomain transcription factor family with a critical role
in controlling embryonic development and differentia-
tion. It activates the expression of a set of genes in the
thyroid gland and lung, and is also expressed in basal
ganglia neurons, cortical interneurons, hypothalamic
neurons, ependymal cells of the third ventricle, tany-
cytes and pituicytes. Deletion of T/EBP (TTF-1) in mice
results in defects in the ventral region of the forebrain.
The oncogenic role of TTF-1 remains enigmatic. Cur-
rent evidence indicates that gene networks regulated
by NKX2-1/TTF-1 might be different in normal and
neoplastic tissues and even among different tumour
types [5-8].
We document four primary epithelial tumours of the
sella with striking papillary architecture and intense
TTF-1 nuclear expression. We propose the descriptive
name of primary papillary epithelial tumour of the sella
(PPETS) to define the entity and suggest PPETS could
represent the sellar equivalent of thyroid-like low-grade
nasopharyngeal papillary adenocarcinoma (TL-
LGNPPA) [9-11]. Given their similarities, PPETS and
tumours previously documented as sellar eCCP may
represent the same entity. PPETS expands the spectrum
of TTF-1 expressing tumours of the sellar region and its
existence challenges the view that TTF-1-positive
tumours of the infundibulum invariably derive from
pituicytes [12-14].
Patient histories
Patient 1 A 20-year-old female presented with a
3-month history of headache and secondary
amenorrhoea for the last 5 months. On examination,
she had bitemporal haemianopia. Her visual field defect
gradually progressed and she also developed diplopia.
She was otherwise well, and her neurological
examination was normal. Pituitary hormones were as
follows: Prolactin 50.2 ng/ml (women 4.79–23.3 ng/ml);
GH 0.7 (basal < 1 ng/ml); ACTH 18 (5–60 pg/ml); TSH
2.74 (0.27–4.2 micro IU/ml); FSH 8.51 (women 3.5–
12.5 mIU/ml); LH 3.65 (women 2.4–12.6 mIU/ml).
Clinical and biochemical features were consistent with
normo-gonadotropic hypogonadism.
A Magnetic Resonance Imaging (MRI) scan showed a
solid and cystic, heterogeneously enhancing intrasellar
tumour measuring 45 x 35 x 25 mm, encroaching on
the optic chiasm and extending to the third ventricle.
The sellar floor was intact. No extension into the cav-
ernous sinuses was noted, corresponding to Knosp
grade 2 [15]. A preoperative diagnosis of pituitary
macroadenoma was considered. A month after onset,
the patient underwent a trans-nasal, trans-sphenoidal
approach with gross total excision of the tumour. Sub-
sequently, she was put on hormone replacement and
remained well for the following 10 months when she
returned to clinic complaining of visual disturbances
and headache. An MRI documented tumour regrowth.
The recurrence measured 37 x 30 x 25 mm and simi-
lar to the primary tumour, it did not invade the adja-
cent bone or extend to the cavernous sinus. The
recurrence was again removed trans-sphenoidally.
Extensive investigations including total body MRI, thy-
roid ultrasound and PET scan returned negative results.
She has been kept on hormone replacement because
investigations did not reveal any other lesions. The
patient has been on close follow-up and she is well and
free of disease at the last visit 51 months after surgery.
Patient 2 This 26-year-old female presented with a
short history of amenorrhoea. She had her first
menstrual cycle at the age of 13 years, but her cycles
had always been irregular. For this reason, she had
been on combined systemic oestrogen and progesterone
replacement therapy for five years, which was
suspended 4 years before her current presentation. Her
family history included diabetes, dyslipidaemia, glioma
and breast cancer in distant relatives. More recently,
she also developed galactorrhoea. Prolactin level was
52.45 ng/dL (0min) and 50.05 ng/dl (120 min)
(normal range: 2–27 ng/ml).
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An MRI study of the sella documented a solid and cys-
tic lesion measuring 18x26x18mm that returned a
hyperintense signal on T2-weighted sequences apart
from a hypointense component towards the sellar floor.
The lesion enhanced after gadolinium administration
and impinged on the optic chiasm and third ventricle
(Figures 1A,B). No extension to the cavernous sinuses
was present (Knosp grade 2). The possibility of cranio-
pharyngioma was suggested preoperatively. A CT-scan
demonstrated thinning of the sellar floor and possible
breach of the bone with possible small extension to the
sphenoid sinus. No other lesions with the nasal cavities
or sphenoid sinus were observed. On confrontation,
visual field exam was normal on both sides. Her hor-
monal status included central hypoadrenalism (peak cor-
tisol 9.8 lg/dl, ACTH 7.8 pg/ml) and central
hypothyroidism (fT4 5.1 pmol/l, TSH 2.7 mU/l). Prior to
surgery, she was therefore commenced on thyroxine,
hydrocortisone and vitamin D supplement. She under-
went transsphenoidal surgery with gross total removal
of the lesion. She developed diabetes insipidus postopera-
tively, treated with desmopressin acetate 60 lg 1cp/day.
Following surgery, ACTH secretion returned to normal-
ity and her adrenal and thyroid function recovered. Hor-
mone replacement therapy was therefore suspended
2 months after surgery. Given the histological diagnosis,
she was extensively investigated with total body CT-scan
and FdG PET and no other lesions were discovered. At
the last follow-up visit a year after surgery, she had nor-
mal thyroid, adrenal and GH functions. Conversely,
normo-gonadotropic hypogonadism persisted, requiring
adequate supplementation therapy. Diabetes insipidus
resolved. MRI showed no evidence of recurrent disease.
Patient 3 This 49-year-old male patient was identified
by reviewing retrospectively the cases referred to the
Department of Pathology and Laboratory Medicine at
Mayo Clinic, Rochester, MN. The clinical history and
tissue available for review are therefore limited. The
patient presented to medical observation with visual
symptoms. Neuroimaging documented a solid and
cystic pituitary mass that was diagnosed as
nonfunctioning pituitary adenoma, for which he
underwent transsphenoidal surgery.
Given the papillary architecture, the lesion was
diagnosed as possible metastasis from a thyroid pri-
mary. The patient underwent a total thyroidectomy
that revealed two foci of papillary microcarcinoma
(PMC) measuring 3 mm and 1.5 mm respectively. No
evidence of disease elsewhere was found including
loco-regional lymph nodes with total body CT-scan
and 131I-scan. A conservative treatment plan was pur-
sued and the patient was under regular followed up.
Eight years after transsphenoidal surgery, he under-
went a nephrectomy for a chromophobe renal cell
carcinoma and three years later, he developed chronic
renal failure. He also developed seizures, which are
controlled medically. At the last available follow-up,
11 years from the original presentation, he had no
evidence of a pituitary recurrence or of any metastatic
deposits from his PMC.
Patient 4 A 42-year-old female presented with
paraesthesia in the upper limbs, more evident at the
left site with numbness in the territory of the third
branch of trigeminal nerve. No other neurological
defects were found. She did not have a visual field
Figure 1. (Patient 2): Pre (A) and postcontrast (B) T1-weighted sagittal sequences document a solid and cystic lesion expanding the sella
and extending to the third ventricle.
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defect on confrontation. Pituitary hormones levels were
normal. She underwent brain MRI, which showed a
sellar and suprasellar solid and cystic lesion measuring
20 x 16 x 28 mm with calcification (Figure S1a and
Figure S1b). The optic chiasm was compressed. No
compression of the third, fourth and sixth cranial
nerves or invasion of the cavernous sinus was present.
She underwent trans-sphenoidal surgery leading to a
gross total removal of the lesion. Postoperatively, she
developed transient diabetes insipidus and adrenal
cortical insufficiency, initially treated with
desmopressin and steroids but it then resolved. No
other tumour was found outside the sella.
Methods
Tissue from the four tumours and recurrence of patient
1 were fixed in formalin and processed to paraffin
embedding. Five-micron-thick sections were cut from
each block and stained with haematoxylin–eosin
(H&E), Periodic Acid Schiff (PAS), PAS following dias-
tase treatment and Masson-Fontana and Gordon–
Sweet’s silver impregnation for reticulin fibres. The
lesions from patients 1, 2 and 4 were investigated with
immunohistochemistry on a BenchMark ULTRA Slide
Staining System (Roche Diagnostics, Indianapolis, IN,
USA), using the following primary antibodies directed
against: pancytokeratin (Novocastra Newcastle UK;
cocktail monoclonal AE1 and AE3; dilution 1:50),
cytokeratin 7 (Dako Agilent Stockport UK, monoclonal
OV-TL 12/3, dilution 1:50), cytokeratin 8 (Becton
Dickinson San Jose CA, monoclonal CAM5.2; dilution
1:50), cytokeratin 20 (Dako Agilent, Ks20.8; dilution
1:50), EMA (Novocastra, monoclonal GP1.4; dilution
1:500), TTF-1 (Novostastra, monoclonal clone SPT24;
dilution 1:50; Dako Agilent, 8G7G3/1; dilution 1:100),
CDX2 (Cell Marque, Rocklin, California, USA, mono-
clonal AMT28, dilution 1:50), b-catenin (Ventana/
Roche, monoclonal clone 14; dilution 1:1), chromo-
granin A (Dako Agilent, monoclonal Dak-A3; dilution
1:200), synaptophysin (Novocastra, monoclonal
27G12; dilution 1:500), vimentin (Dako Agilent, mon-
oclonal SRL-33; dilution 1:200), GFAP (Dako Agilent,
monoclonal 6F2; dilution 1:1000), S-100 protein (Dako
Agilent; polyclonal; 1:1000); Napsin A (Novocastra,
monoclonal IP64; dilution 1:500), thyroglobulin (Dako
Agilent, DAK-Tg6; dilution 1:100), HMB45 (Dako Agi-
lent, monoclonal M0634; dilution 1:50), PAX8
(Proteintech, polyclonal; dilution 1:250), Transthyretin
(Novocastra, polyclonal; dilution 1:100), LIN28A
(Abcam, Cambridge UK, rabbit polyclonal, dilution
1:100), OLIG-2 (Abcam, rabbit polyclonal, dilution
1:200), cKIT (CD117) (Leica Biosystem, Breckland, Lin-
ford Wood, Milton Keynes, UK, monoclonal NCL-L-
CD117, dilution 1:300), alpha-fetoprotein (Dako Agi-
lent, rabbit polyclonal, dilution 1:500), OCT3/4 (Leica
Buffalo Grove, USA, mouse monoclonal NCL-L-OCT3/4,
dilution 1:100), Ki-67 (Dako Agilent; monoclonal MIB-
1, dilution 1:100), INI-1 (Cell Marque, monoclonal
MRQ27; dilution 1:500), FSH (Cell Marque Darmstadt
Germany, monoclonal 83/122A8; 1:2000), LH (Cell
Marque, monoclonal 3LH5B6Y; dilution 1:100), TSH
(Cell Marque, monoclonal 5404; dilution 1:50), PRL
(Biogenex, monoclonal BGX031A; dilution 1:50),
ACTH (Dako Agilent, monoclonal, clone 02A3; dilution
1:1000), GH (Cell Marque, monoclonal 54/92A2; dilu-
tion 1:50), Steroidogenic Factor 1 (Abcam Cambridge
UK, monoclonal EPR19744; 1:150), PIT1 (Novus Bio-
logicals Abingdon Oxon UK, polyclonal; dilution
1:100), TPIT (Atlas Antibodies, Stockholm Sweden;
monoclonal CL6251; 1:300), EGFR (Dako Agilent,
clone H11, code M3563; dilution 1:50), BRAFV600E
(Ventana, VE1 clone; prediluted) and CD68 (Dako Agi-
lent, clone KP1; dilution 1:200).
A limited immunopanel including AE1 and AE3,
cytokeratin 7, cytokeratin 8, EMA, TTF-1 (clone
SPT24), GFAP, S-100, thyroglobulin and pituitary hor-
mones was available for the tumour from patient 3.
The paraffin block of this patient was disposed of
10 years after surgery. No further immunostains or
molecular analysis was possible.
The Ki-67 labelling index was calculated as the num-
ber of positive cells out the overall number of neoplastic
cells in three different fields at the magnification of x40
as previously recommended [16].
Electron microscopy
A fragment from the primary tumour of patient 1 was
retrieved and reprocessed for electron microscopy from
the paraffin block. After dewaxing in xylene and rehy-
dration to distilled water, the fragments were fixed in
3% glutaraldehyde, post-fixed in 1% osmium tetroxide
and embedded in Taab-812 epoxy resin (Merck, Darm-
stadt Germany). The quality of specimen was checked
on Toluidine-blue stained semithin sections.
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Ultrastructure was examined with a JEM1400 plus
transmission electron microscope (Joel, Peabody MA
01960, USA).
Next-generation sequencing
For patients 1 (recurrence) and 2, genomic DNA was
isolated from the formalin-fixed and paraffin-embedded
tumour samples using the cobas DNA Sample Prepa-
ration Kit (Roche Diagnostics Ltd Burgess HillUK), a
generic manual specimen preparation based on nucleic
acid binding to glass fibres. Sequence analysis was car-
ried out following PCR enrichment using a QIAseq Tar-
geted DNA custom panel (Qiagen, Germantown, MD,
USA) and Illumina Next Generation Sequencing (Illu-
mina, San Diego CA, USA).
The panel targeted 37 commonly mutated oncogenes
(AKT1, ALK, AR, ATRX, B2M, BRAF, CDKN2A,
CTNNB1, DDR2, EGFR, ERBB2, FGFR3, GNA11,
GNAQ, GNAS, H3F3A, H3F3B, HIST1H3B, HIST1H3C,
HIST2H3C, HRAS, IDH1, IDH2, KIT, KRAS, MAP2K1,
MET, NRAS, PDGFRA, PIK3CA, PTEN, RET, STK11,
TERT, TP53, VHL), however, the whole coding
sequence of all 37 genes was not targeted. Mutation
and variant calling by custom bioinformatics analysis
pipeline validated to detect SNVs and small insertion/
deletion mutations (<40bp) to 5% mutant allele fre-
quency. Alterations were categorized following Ameri-
can College of Medical Genetics guidelines and
Association for Molecular Pathology tiering.
For the tumour of patient 4, the NGS panel in use
at the University Hospital of Lausanne was tested at
the time of initial diagnosis and not repeated for this
study in tumours 1 and 2. DNA was isolated from the
formalin-fixed and paraffin-embedded tumour sample
and an amplicon-based DNA library was prepared
using a customized primer panel targeting hotspot
regions of 52 genes relevant to cancer (custom Ion
AmpliSeq panel, Ion Torrent, Thermo Fisher Scientific,
Waltham, MA, USA), and subsequently sequenced on
an Ion S5 System (Ion Torrent, ThermoFisher Scien-
tific, Waltham, MA, USA).This NGS panel included 27
of the 37 genes tested in patients 1 and 2 and also
the following 25 gene:ABL1, APC, ATM, CDH1,
CSF1R, ERBB4, EZH2, FBXW7, FGFR1, FGFR2,
FLT3, HNF1A, JAK2, JAK3, KDR, MLH1, MPL,
NOTCH1, NPM1, PTPN11, RB1, SMAD4, SMARCB1,
SMO and SRC.
AR, ATRX, B2M, GNA11, H3F3A, H3F3B,
HIST1H3B, HIST1H3C, HIST2H3C, hTERT were not
investigated in patient 4.
Results
The four primary tumours and the recurrence of patient 1
showed similar papillary architecture, although some
variation between cases was observed. The papillae con-
sisted of a single layer of tightly packed cylindrical or
cuboidal cells lining a fibro-vascular core; pseudostratifi-
cation of tumour cells was seen, particularly in cases 2, 3
and 4 (Figures 2, 4, 5A, 7B). The neoplastic cells had eosi-
nophilic cytoplasm and round to ovoid, slightly hyper-
chromatic nucleus with dense chromatin and
inconspicuous nucleolus. No nuclear inclusions or groves
were identified (Figures 5A and 7B). The connective tis-
sue of the fibro-vascular cores was oedematous in some
papillae and compact and hyalinized in others. In cases 1
and 4, the core of several papillae contained lymphocytic
infiltrates admixed with plasma cells (Figure 2A) and
foamy histiocytes (Figure 7B). A few multinucleated
giant cells were present in cases 1 and 2 (Figures 5B).
Focal squamous metaplasia was found in case 1 (Fig-
ure 2B). No glands or evidence of intra or extracellular
mucin production, ciliated or pigmented cells were
observed. There was focal microcalcification in cases 2, 3
and 4. Specimens from patient 1 and 2 contained frag-
ments of anterior hypophysis without pathological fea-
tures of note. No neurohypophysis was present. No
mitoses were identified. There were haemosiderin-laden
macrophages and extravasation of red blood cells in cases
1 and 2. Necrosis was present in cases 1 and 4 (Fig-
ure 7A). There was no evidence of bone invasion.
The neoplastic cells expressed CK7 (Figure 3A) and
showed focal expression of cytokeratin AE1/AE3, cytok-
eratin CAM5.2 and cytoplasmic and apical expression of
EMA (Figure S2). Tumours 3 and 4 showed focal CK7
and diffuse AE1/AE3 expression. Vimentin was
expressed focally in cases 2 (Figure 6A) and 4, whereas
it was negative in case 1 and it was not tested in patient
3. TTF-1 expression was intense and ubiquitous in all
lesions (Figures 3B), apart from cells showing squamous
metaplasia in case 1. Expression of INI-1 was retained.
Multinucleated giant cells (cases 1 and 2) and foamy
macrophages were CD68 positive. Immunoreactions for
pituitary hormones and transcription factors, synapto-
physin, chromogranin, CK20, GFAP, S-100 protein,
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transthyretin, Napsin A, thyroglobulin, PAX8, p53,
EGFR, BRAFV600E, CDX2, LIN28A, OLIG-2, cKIT,
alpha-fetoprotein and OCT3/4 were negative. Both pri-
mary and the recurrent lesions showed Ki-67 labelling
indices lower than 1% (Figure 6B).
Ultrastructural examination was attempted in pri-
mary tumour of patient 1. Preservation of tissue for EM
was suboptimal following retrieval from paraffin. Nev-
ertheless, it showed microvilli, intercellular tight junc-
tions (Figure S3) and intermediate filaments further
confirming the epithelial origin of the lesion. There
were no excess mitochondria or lysosomes, and there
was no evidence of cilia, intracytoplasmic vacuoles or
membrane-bound neurosecretory granules.
Next-generation sequencing
The recurrent tumour of patient 1 and the primary
lesion of patients 2 and 4 did not show any relevant
variants in the genes examined. No tissue was available
from patient 3 for next-generation sequencing.
Incidence of PPETs
In order to understand the frequency of PPETS, we
reviewed the diagnostic database of the Department of
Cellular Pathology at Salford Royal Foundation Trust,
the Department of Pathology at PIGMER in Chandigarh
and the Cellular Pathology Department at Humanities
in Milan. A total of 3139 cases were found between
January 2008 and December 2018. The original slides
of 21 pituitary metastases operated on in the three
institutions including a lung micro papillary adenocar-
cinoma were reviewed. No diagnoses of sellar ependy-
moma or sellar choroid plexus papilloma and no PPETS
other than the lesions reported here were found indi-
cating that PPETS accounts for less than 0.1% of sellar
tumours operated on in our institutions in an 11-year
period.
Discussion
We have documented four primary intra and suprasel-
lar epithelial tumours with papillary architecture and
TTF-1 expression, for which we propose the descriptive
term of PPETS. The lesions occurred in three females
and one male, all presenting with signs and symptoms
of mass effect. Neuroimaging features of the four
lesions were similar and included cystic and solid,
enhancing component, extension to the third ventricle
with chiasmatic compression but no involvement of the
cavernous sinuses. Invasion of the sellar floor was sug-
gested in the preoperative MRI in case 2. Primary Pap-
illary Epithelial Tumour of the Sella is extremely rare.
We only found two examples in over 3000 tumours
operated trans-sphenoidally in our institutions and no
Figure 2. (Patient 1 – primary): Cells lying papillae often show with apical snouting (A, haematoxylin–eosin – x10); focal squamous
metaplasia is present (B, zhaematoxylin–eosin – x20).
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mention of a similar lesion is reported in large review
of over 7000 sellar and suprasellar lesions recently
published by Abushamat and colleagues [17], further
emphasising the rarity of PPETS.
The absence of pituitary hormone and pituitary lin-
eage restricted transcription factors ruled out the pos-
sibility of a primary tumour of adenohypophyseal
cells. Given the papillary architecture, and the expres-
sion of cytokeratins and TTF-1, PPETS was distin-
guished from a metastatic papillary thyroid carcinoma
(PTC) or lung micropapillary carcinoma [18]. The
patients were carefully investigated over the years. No
primary tumours outside the sella were found in
patients 1, 2 and 4. The immunoprofile of their
lesions including the absence of thyroglobulin or nap-
sin expression, and the bland light microscopic fea-
tures were not in keeping with a metastatic deposit.
Next-generation sequencing did not show any muta-
tions in BRAF, HRAS and KRAS genes that are com-
monly mutated in PTC [19]. Finally, the absence of
CDX2 expression excluded the diagnosis of columnar
variant of PTC [20,21]. Patient 3 underwent thy-
roidectomy and was found to have two microscopic
foci of PTC, respectively, measuring 1.5 mm and
3 mm. The original slides from his thyroid primary
lesions were reviewed. The features were typical of
PTC, including thyroglobulin expression and were
therefore different from his sellar lesion. Papillary thy-
roid carcinomas smaller than 1.0 cm are defined as
PMC. They are a common disease [22-24]. In several
countries, the availability of more accurate diagnostic
techniques along with increased medical surveillance
has led to a considerable increase in the detection of
incidental PMC without a corresponding increase in
mortality [25]. Low-risk PMC is an indolent disease
that does not grow or grows very slowly and only
very rarely spreads to neck lymph nodes [26-28]. For
this reason, the absence of any metastatic deposits in
Figure 3. (Patient 1 – recurrence): Neoplastic cells express cytokeratin 7 (A, immunoperoxidase – x10) and show nuclear TTF-1
expression (B, immunoperoxidase – x4).
Figure 4. (Patient 2): Papillae in this tumour are less cohesive
than case 1; fibro-vascular cores contain foamy macrophages; no
lymphocytes or plasma cells are present in this area
(Haematoxylin–eosin – x4).
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lymph nodes in patient 3 during the 11-year follow-
up would be unusual for PTC. Also, pituitary deposits
from PTC are exceedingly rare accounting for 2–3%
of all pituitary metastases [29-32]. Metastases to the
sella occur more often in patients who have an estab-
lished diagnosis of PTC. Notably, immunostains to
confirm the diagnosis of metastatic PTC to the pitu-
itary were only performed in a few cases [reviewed in
ref 33]. The question of whether a few of the
documented metastatic PTC to the pituitary could
have been examples of PPETS and the primary thyroid
lesion an incidental finding remains open.
Rare primary tumours with papillary architecture
have previously been described in the sella and
regarded as examples of extraventricular eCPP [34-37].
Sellar eCPP and PPETS are very similar, and although
none of the published examples of sellar eCPP were
tested for TTF-1, they could represent the same entity.
Figure 5. (Patient 2): Tumour cells can at times be tightly packed and show pseudostratification (A, haematoxylin–eosin – x10).
Multinucleated giant cells are seen in the stalk of papillae (B, haematoxylin–eosin – x20).
Figure 6. (Patient 2): Several tumour cells express vimentin (A, immunoperoxidase – x10); less than 1% of neoplastic cells are positive
for Ki-67 (B, immunoperoxidase – x4).
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Reported sellar eCPPs present as solid or solid/cystic,
sellar and suprasellar lesions without cavernous sinus
extension or breach of the sellar floor. Unlike conven-
tional CPPs [38,39] and similar to PPETS, sellar eCPPs
show diffuse expression of cytokeratin 7 and focal
expression of EMA and lack of cytokeratin 20 and S-
100 protein. Vimentin was positive in two examples
[36,37]. Transthyretin was only tested in one sellar
eCPPs and it was reportedly positive [37]. In addition,
the suggested origin of sellar eCPPs from ectopic chor-
oid plexus rests in the sella has never been substanti-
ated. The exceedingly rare pigmented papillary
epithelial neoplasm of the pituitary fossa was excluded
based on the immunoprofile as they contain melanin
and express transthyretin, S100, Vimentin and HMB45
and are negative for EMA and pancytokeratin. TTF-1
was neither tested in the original description nor in a
more recently reported case [40,41]. One case of pri-
mary sellar papillary adenocarcinoma was documented
by Hampton and colleagues as part of the spectrum of
primary sellar tumours that arise from ectopic salivary
gland remnants in the pars intermedia [42]. Unlike our
four cases, the lesion exhibited overtly aggressive fea-
tures including nuclear atypia and pleomorphism,
prominent nucleoli, frequent atypical mitosis and
necrosis.
Sellar ependymoma enters the differential diagnosis
with PPETS. Sellar ependymoma belongs to the group
of TTF-1-positive posterior pituitary tumours. Its
reported features vary from those of a classic ependy-
moma with ependymal and perivascular rosettes to
lesions that consist of sheets and fascicles, but it is best
regarded as a variant of pituicytoma [1,43,44]. In addi-
tion to TTF-1 expression, the immunoprofile of sellar
ependymoma includes S-100 protein and dot-like
rather than cytoplasmic, apical EMA. Ultrastructural
evidence of intra and intercellular lumina containing
microvilli and cilia and cell-to-cell junctions that are
reminiscent of pituicytes with ependymal differentiation
help confirm the diagnosis [14]. Unlike PPETS, cytoker-
atin is only focally expressed in sellar ependymoma.
Given the unusual features of PPETS, the vicinity of
sella and sphenoid sinus and the possible breach of sel-
lar floor in patient 2, we considered nonsalivary and
nonintestinal type low-grade adenocarcinoma of the
sinonasal tract (SNAC) in the differential diagnosis. His-
tologically, low-grade SNACs can show papillary fea-
tures, but they are more often composed of back-to-
back glands and tubules with little or no intervening
stroma. Cribriform and trabecular growth are also
described [45-47]. As seen in PPETS, papillae and
tubules are lined by a single layer of uniform columnar
or cuboidal cells showing minimal atypia, but they typ-
ically lack TTF-1 expression. Also, the distinctive
expression of vimentin in the basal part of the neoplas-
tic cells in ETV6 SNAC [46] was not a feature of
PPETS. In contrast, the light microscopic features and
immunoprofile of PPETS are remarkably similar to TL-
Figure 7. (Patient 4): the whole mount (A) of this tumour demonstrates areas of haemorrhagic necrosis (asterisk) accounting for the
cystic component seen in the preoperative neuroimaging. The core of papillae contains lymphocytes, plasma cells and foamy histiocytes
(B, haematoxylin–eosin, x20).
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LGNPPA [9-11,48]. Review of neuroimaging and intra-
operative inspection confirmed the sellar floor was
intact in our patients, and no nasal or pharyngeal
lesion was present. This supported the view that the
lesions documented here originated from the sella
despite similarity with TL-LGNPPA. TL-LGNPPA is
extremely rare. First documented by Wenig et al. in
1988 [9] as a distinct entity, TL-LGNPPA has been
included into the WHO classification of head and neck
tumours in 2005 as a malignant neoplasm of
nasopharynx. Striking papillary architecture and aber-
rant TTF-1 expression that mimic papillary thyroid car-
cinoma are its distinguishing features. Examples of TL-
LGNPPA reported so far always present as polypoid
intranasal masses, originating from the roof of the
nasopharynx and posterior edge of the nasal septum,
and with sizes up to 4 cm. No examples occurring in
the sphenoid sinus have been documented. Adenocarci-
noma is a misnomer as surgery is curative and progno-
sis is excellent [10-11,48]. No local recurrence or
metastatic spread has been reported.
The cell of origin of PPETS remains unclear. Ubiqui-
tous, intense nuclear expression of TTF-1 suggests the
derivation from the pituitary infundibulum, median emi-
nence or the organum vasculosum of the lamina termi-
nalis rather than the anterior gland. TTF-1 is not
expressed in the anterior hypophysis [49], whereas none
of the above TTF-1-positive structures have been reported
to contain cytokeratin-positive cells. The neurohypoph-
ysis, organum vasculosum of the lamina terminalis and
median eminence belong to the circumventricular organs
(CVO), a complex of highly vascularized, midline struc-
tures lacking the normal blood–brain barrier [50,51].
Recent evidence suggests that the entire roof of the third
ventricle is a common CVO progenitor domain and stem
cell properties of CVO have been demonstrated in an ani-
mal model [52]. These findings might suggest the poten-
tial of stem cells to differentiate toward an epithelial
phenotype giving rise to PPETS. On the other hand, TTF-
1 is not restricted to tumours of the infundibulum. Using
tissue microarrays, Kristensen and colleagues [53] com-
pared the two anti-TTF-1 clones 8G7G3/1 and SPT24 in
a wide spectrum of 155 primary CNS tumours. In addi-
tion to a minority of high-grade gliomas, they observed
weak and focal expression in central neurocytoma, one
ependymoma and one choroid plexus papilloma. Using
the clone SPT24 of anti-TTF-1 antibody, Zamecnik et al.
only observed TTF-1 in two ependymomas, whereas none
of the other primary CNS lesion they investigated was
positive [54]. More recently, Asa and colleagues observed
weak TTF-1 expression in sellar neurocytoma [55].
In conclusion, we have documented a novel primary
sellar tumour with striking papillary architecture, cytok-
eratins and TTF-1 expression. This entity expands the
spectrum of TTF-1-expressing primary tumours of the
third ventricle, infundibulum and sella. The lesion
should be distinguished from sellar metastases from thy-
roid and lung, sinonasal low-grade adenocarcinomas
and sellar ependymomas. We suggest that PPETS and
sellar eCPPs may be the same tumour type and represent
the intracranial equivalent of TL- LGNPPA.
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Figure S1. (Patient 4): the tumour of patient 4 shows
heterogenous enhancement of the solid areas (A, sagit-
tal postcontrast T1-weighted sequence); no invasion of
cavenous sinues is present (B, axial postcontrast T1-
weighted sequence).
Figure S2. (Patient 4): neoplastic cells show cytoplasmic,
apical expression of EMA (immunoperoxidase, x20).
Figure S3. Ultrastructural examination of tissue repro-
cessed from paraffin shows intercellular tight junction
(arrow) (orignal magnification x 1 2,000; printed mag-
nification x 59,000) (Patient 1, primary tumour).
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